Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
Submitted by
admin
on December 2, 2015 - 9:28am
Source:
Yahoo
News Tags:
AbbVie
hepatitis C
Viekira Pak
Headline:
AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
Do Not Allow Advertisers to Use My Personal information
